MedTrace Logo

Long-term Effect of Lanthanum Carbonate on Bone

NCT00557323 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2021-07-13

Study results available
· View outcomes & findings →

Summary

Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.

Conditions

  • Hyperphosphatemia

Interventions

DRUG

Lanthanum carbonate

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-15
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00557323 on ClinicalTrials.gov